Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

vitamin D3 analogue ILX23-7553

A vitamin D3 analogue with potential antineoplastic activity. ILX23-7553 binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, ILX23-7553 may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:16-23-D3
Code name:BXL 353
ILEX 23-7553
ILX 237553
ILX-237553
ILX23 7553
ILX23-7553
ILX237553
RO 237553
RO-237553
Ro23-7553
RO237553
Chemical structure:1,25-dihydroxy-16-ene-23-yne-cholecalciferol
9,10-secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol, (1alpha,3beta,5Z,7E)-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search